TIL - Instil Bio, Inc.

8.055
-0.125   -1.552%

Share volume: 23,677
Last Updated: 04-24-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$8.18
-0.13
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 29%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.99%
1 Month
-6.34%
3 Months
13.93%
6 Months
-59.46%
1 Year
-36.97%
2 Year
-59.73%
Key data
Stock price
$8.06
P/E Ratio 
N/A
DAY RANGE
$7.62 - $8.39
EPS 
-$9.39
52 WEEK RANGE
$5.67 - $42.79
52 WEEK CHANGE
-$35.25
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
6.782 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$24,164
AVERAGE 30 VOLUME 
$29,752
Company detail
CEO: Bronson Crouch
Region: US
Website: instilbio.com
Employees: 410
IPO year: 2021
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL) Product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, and cervical cancer.

Recent news